Jay N. Cohn

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

Karl Swedberg, Richard B. Devereux, Ralph L. Sacco, 2011, Journal of hypertension.

Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure: Results From the Valsartan Heart Failure Trial

J. Cohn, R. Latini, S. Masson, 2003, Circulation.

Vasodilator Therapy of Cardiac Failure

J. Cohn, J. Franciosa, Jay N. Cohn, 1977 .

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

Gianni Tognoni, Simona Barlera, Steven N. Singh, 2005 .

Arterial Vascular Compliance In Heart Failure

Stanley M. Finkelstein, Gary E. McVeigh, Jay N. Cohn, 1990, [1990] Proceedings of the Twelfth Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

Safety and efficacy of carvedilol in severe heart failure

Milton Packer, Michael R. Bristow, Michael B. Fowler, 1997 .

Vascular compliance in hypertension

Stanley M. Finkelstein, Jay N. Cohn, Peter F. Carlyle, 1988, Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial).

Gianni Tognoni, Simona Barlera, J. Cohn, 2008, Journal of the American College of Cardiology.

Consensus recommendations for the management of chronic heart failure: Introduction

Thomas D. Giles, William T. Abraham, John B. Kostis, 1999 .